Thalidomide: Mechanisms of action and new insights in hematology;Thalidomide: Mécanismes d'action et indications en hématologie

Revue de Medecine Interne

Volumn 26, Issue 2, 2005, Pages 119-127

  Leleu, X ^a   Micol, J B ^a   Guieze, R ^a   Berthon, C ^a   Kuhnovsky, F ^a   Terriou, L ^a   Moreau, A S ^a   Yakoub Agha, I ^a   Bauters, F ^a   Facon, T ^a  

^a LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

Blood disease; Multiple myeloma; Pharmacology; Thalidomide

Indexed keywords

CYTOKINE; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA;

ANTIANGIOGENIC ACTIVITY; CONSTIPATION; CYTOKINE RELEASE; DEPRESSION; DRUG ACTIVITY; DRUG ERUPTION; DRUG MECHANISM; DRUG RESPONSE; EDEMA; FATIGUE; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNOMODULATION; LYMPHOPOIESIS; MOTOR DYSFUNCTION; MULTIPLE MYELOMA; NEUROPATHY; RELAPSE; REVIEW; SOMNOLENCE; STRUCTURE ACTIVITY RELATION; THROMBOEMBOLISM; TREATMENT INDICATION; TREMOR; VERTIGO; XEROSTOMIA;

EID: 13844308994     PISSN: 02488663     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.revmed.2004.06.017     Document Type: Short Survey

References (91)

1. Hales B.F. Thalidomide on the comeback trail Nat Med 5 1999 489 490
2. Lenz W. Kindliche missblidungen nach medikament-einnahme wahrend der gravidtat? Disch Med Wochenschr 86 1961 2555 2556
3. Mc Bride W.G. Thalidomide and congenital anomalies Lancet 2 1961 1358
4. Castilla E.E., Ashton-Prolla P., Barreda-Mejia E., Brunoni D., Cavalcanti D.P., and Correa-Neto J. Thalidomide, a current teratogen in South America Teratology 54 1996 273 277
5. Stephens T.D. Proposed mechanisms of action in thalidomide embryopathy Teratology 38 1988 229 239
6. Parman T., Wiley M.J., and Wells P.G. Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity Nat Med 5 1999 582 585
7. Matthews S.J., and McCoy C. Thalidomide: a review of approved and investigational uses Clin Ther 25 2003 342 395
8. Eriksson T., Bjorkman S., Roth B., and Hoglund P. Intravenous formulations of the enantiomers of thalidomide: pharmacokinetic and initial pharmacodynamic characterization in man J Pharm Pharmacol 52 2000 807 817
9. Klausner J.D., Kaplan G., and Haslett P.A. Thalidomide in toxic epidermal necrolysis Lancet 353 1999 324
10. Gupta D., Treon S.P., Shima Y., Hideshima T., Podar K., and Tai Y.T. Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications Leukemia 15 2001 1950 1961
11. Meierhofer C., and Wiedermann C.J. New insights into the pharmacological and toxicological effects of thalidomide Curr Opin Drug Discov Devel 6 2003 92 99
12. Geitz H., Handt S., and Zwingenberger K. Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade Immunopharmacology 31 1996 213 221
13. Settles B., Stevenson A., Wilson K., Mack C., Ezell T., and Davis M.F. Down-regulation of cell adhesion molecules LFA-1 and ICAM-1 after in vitro treatment with the anti-TNF-alpha agent thalidomide Cell Mol Biol 47 2001 1105 1114
14. Zwingenberger K., and Wnendt S. Immunomodulation by thalidomide: systematic review of the literature and of unpublished observations J Inflamm 46 1995 177 211
15. Barkley A.S.J., Bather P.C., and Allen B.R. Retionids enhance monocyte/endothelium interaction J Invest Dermatol 89 1987 320
16. Payvandi F., Wu l., Haley M., Gupta D., Zhang L., and Schafer P. Thalidomide analogs IMiDs inhibit expression of cyclooxygenase-2 in multiple myeloma cell line and LPS stimulated PBMCs Blood 98 2001 641a
17. Attiga F.A., Fernandez P.M., Weeraratna A.T., Manyak M.J., and Patierno S.R. Inhibitors of prostaglandin synthesis inhibit human prostate tumor cell invasiveness and reduce the release of matrix metalloproteinases Cancer Res 60 2000 4629 4637
18. Hideshima T., Chauhan D., Richardson P., Mitsiades C., Mitsiades N., and Hayashi T. NF-kappa B as a therapeutic target in multiple myeloma J Biol Chem 277 2002 16639 16647
19. Moller D.R., Wysocka M., Greenlee B.M., Ma X., Wahl L., and Flockhart D.A. Inhibition of IL-12 production by thalidomide J Immunol 159 1997 5157 5161
20. Shannon E.J., and Sandoval F. Thalidomide can be either agonistic or antagonistic to LPS evoked synthesis of TNF-alpha by mononuclear cells Immunopharmacol Immunotoxicol 18 1996 59 72
21. Moreira A.L., Wang J., Sarno E.N., and Kaplan G. Thalidomide protects mice against LPS-induced shock Braz J Med Biol Res 30 1997 1199 1207
22. Dunzendorfer S., Herold M., and Wiedermann C.J. Inducer-specific bidirectional regulation of endothelial interleukin-8 production by thalidomide Immunopharmacology 43 1999 59 64
23. Oliver S.J. The Th1/Th2 paradigm in the pathogenesis of scleroderma, and its modulation by thalidomide Curr Rheumatol Rep 2 2000 486 491
24. Corral L.G., Haslett P.A., Muller G.W., Chen R., Wong L.M., and Ocampo C.J. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha J Immunol 163 1999 380 386
25. Folkman J. Tumor angiogenesis: therapeutic implications N Engl J Med 285 1971 1182 1186
26. Gualandris A., Urbinati C., Rusnati M., Ziche M., and Presta M. Interaction of high-molecular-weight basic fibroblast growth factor with endothelium: biological activity and intracellular fate of human recombinant M(r) 24,000:bFGF J Cell Physiol 161 1994 149 159
27. Vacca A., Ribatti D., Presta M., Minischetti M., Iurlaro M., and Ria R. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma Blood 93 1999 3064 3073
28. Rajkumar S.V., Leong T., Roche P.C., Fonseca R., Dispenzieri A., and Lacy M.Q. Prognostic value of bone marrow angiogenesis in multiple myeloma Clin Cancer Res 6 2000 3111 3116
29. Singhal S., Mehta J., Desikan R., Ayers D., Roberson P., and Eddlemon P. Antitumor activity of thalidomide in refractory multiple myeloma N Engl J Med 341 1999 1565 1571
30. Mayo M.W., and Baldwin A.S. The transcription factor NF-kappaB: control of oncogenesis and cancer therapy resistance Biochim Biophys Acta 1470 2000 M55 62
31. Keifer J.A., Guttridge D.C., Ashburner B.P., and Baldwin A.S. Jr Inhibition of NF-kappa B activity by thalidomide through suppression of IkappaB kinase activity J Biol Chem 276 2001 22382 22387
32. 2, but not that activated by ceramide, lipopolysaccharides, or phorbol ester J Immunol 168 2002 2644 2651
33. Barnhill R.L., Doll N.J., Millikan L.E., and Hastings R.C. Studies on the anti-inflammatory properties of thalidomide: effects on polymorphonuclear leukocytes and monocytes J Am Acad Dermatol 11 1984 814 819
34. Davies F.E., Raje N., Hideshima T., Lentzsch S., Young G., and Tai Y.T. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma Blood 98 2001 210 216
35. Hideshima T., Chauhan D., Shima Y., Raje N., Davies F.E., and Tai Y.T. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy Blood 96 2000 2943 2950
36. Hideshima T., Chauhan D., Teoh G., Raje N., Treon S.P., and Tai Y.T. Characterization of signaling cascades triggered by human interleukin-6 vs Kaposi's sarcoma-associated herpes virus-encoded viral interleukin-6 Clin Cancer Res 6 2000 1180 1189
37. Mitsiades C.S., Mitsiades N., Poulaki V., Akiyama M., Chauhan D., and Hideshima T. IGF-1-induced activation of NF-kB and upregulation of intracellular anti-apoptotic proteins in human multiple myeloma cells: therapeutic implications Blood 98 2001 473a
38. Mitsiades N., Mitsiades C.S., Poulaki V., Chauhan D., Richardson P.G., and Hideshima T. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications Blood 99 2002 4525 4530
39. Moreau P. Clinique, bilan, classification et valeur pronostique Oncologie 4 2002 97 101
40. Olson K., Hall T., Horton J., Khung C., and Ghosly H. Thalidomide (N-phthalidoglutarimide) in the treatment of advanced cancer Clin Pharmacol ther 6 1965 292 297
41. Barlogie B., Zangari M., Spencer T., Fassas A., Anaissie E., and Badros A. Thalidomide in the management of multiple myeloma Semin Hematol 38 2001 250 259
42. Barlogie B., Desikan R., Eddlemon P., Spencer T., Zeldis J., and Munshi N. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase two study of 169:patients Blood 98 2001 492 494
43. Yakoub-Agha I., Attal M., Dumontet C., Delannoy V., Moreau P., and Berthou C. Thalidomide in patients with advanced multiple myeloma: a study of 83:patients-report of the Intergroupe Francophone du Myelome (IFM) Hematol J 3 2002 185 192
44. Leleu X., Magro L., Fawaz A., Bauters F., Facon T., and Yakoub-Agha I. Efficacy of a low dose of thalidomide in advanced multiple myeloma Blood 100 2002 1519 1520
45. Durie B.G. Low-dose thalidomide in myeloma: efficacy and biologic significance Semin Oncol 29 2002 34 38
46. Ochonisky S., Verroust J., Bastuji-Garin S., Gherardi R., and Revuz J. Thalidomide neuropathy incidence and clinico-electrophysiologic findings in 42:patients Arch Dermatol 130 1994 66 69
47. Weber D., Rankin K., Gavino M., Delasalle K., and Alexanian R. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma J Clin Oncol 21 2003 16 19
48. Zangari M., Siegel E., Barlogie B., Anaissie E., Saghafifar F., and Fassas A. Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy Blood 100 2002 1168 1171
49. Rajkumar S.V., Hayman S., Gertz M.A., Dispenzieri A., Lacy M.Q., and Greipp P.R. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma J Clin Oncol 20 2002 4319 4323
50. Zangari M., Anaissie E., Barlogie B., Badros A., Desikan R., and Gopal A.V. Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy Blood 98 2001 1614 1615
51. Dimopoulos M.A., Anagnostopoulos A., and Weber D. Treatment of plasma cell dyscrasias with thalidomide and its derivatives J Clin Oncol 21 2003 4444 4454
52. Moehler T.M., Neben K., Egerer G., Punzel M., Schmier J., and Cremer F. Thalidomide plus CED-chemotherapy in patients with poor prognosis multiple myeloma Blood 94 suppl 1999 abstr.547
53. Ghobrial I.M., Dispenzieri A., Bundy K.L., Gastineau D.A., Rajkumar S.V., and Therneau T.M. Effect of thalidomide on stem cell collection and engraftment in patients with multiple myeloma Bone Marrow Transplant 32 2003 587 592
54. Rajkumar S.V., Gertz M.A., Lacy M.Q., Dispenzieri A., Fonseca R., and Geyer S.M. Thalidomide as initial therapy for early-stage myeloma Leukemia 17 2003 775 779
55. Rajkumar S.V., Mesa R.A., Fonseca R., Schroeder G., Plevak M.F., and Dispenzieri A. Bone marrow angiogenesis in 400:patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis Clin Cancer Res 8 2002 2210 2216
56. Seldin D.C., Choufani E.B., Dember L.M., Wiesman J.F., Berk J.L., and Falk R.H. Tolerability and efficacy of thalidomide for the treatment of patients with light chain-associated (Al) amyloidosis Clin Lymphoma 3 2003 241 246
57. Rajkumar S.V., Hayman S., and Greipp P.R. Angiogenesis in Waldenstrom's macroglobulinemia Semin Oncol 30 2003 262 264
58. Dimopoulos M.A., Tsatalas C., Zomas A., Hamilos G., Panayiotidis P., and Margaritis D. Treatment of Waldenstrom's macroglobulinemia with single-agent thalidomide or with the combination of clarithromycin, thalidomide and dexamethasone Semin Oncol 30 2003 265 269
59. Wilson E.A., Jobanputra S., Jackson R., Parker A.N., and McQuaker I.G. Response to thalidomide in chemotherapy-resistant mantle cell lymphoma: a case report Br J Haematol 119 2002 128 130
60. Damaj G., Lefrere F., Delarue R., Varet B., Furman R., and Hermine O. Thalidomide therapy induces response in relapsed mantle cell lymphoma Leukemia 17 2003 1914 1915
61. Thiele J., Rompcik V., Wagner S., and Fischer R. Vascular architecture and collagen type IV in primary myelofibrosis and polycythaemia vera: an immunomorphometric study on trephine biopsies of the bone marrow Br J Haematol 80 1992 227 234
62. Di Raimondo F., Azzaro M.P., Palumbo G.A., Bagnato S., Stagno F., and Sortino G. Elevated VEGF serum levels in idiopathic myelofibrosis Blood 94 suppl.1 1994 116a
63. Jacobson R.J., Salo A., and Fialkow P.J. Agnogenic myeloid metaplasia: a clonal proliferation of hematopoietic stem cells with secondary myelofibrosis Blood 51 1978 189 194
64. Martyre M.C., Le Bousse-Kerdiles M.C., Romquin N., Chevillard S., Praloran V., and Demory J.L. Elevated levels of basic fibroblast growth factor in megakaryocytes and platelets from patients with idiopathic myelofibrosis Br J Haematol 97 1997 441 448
65. Tefferi A. Myelofibrosis with myeloid metaplasia N Engl J Med 342 2000 1255 1265
66. Mesa R.A., Steensma D.P., Pardanani A., Li C.Y., Elliott M., and Kaufmann S.H. A phase two trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia Blood 101 2003 2534 2541
67. Piccaluga P.P., Visani G., Pileri S.A., Ascani S., Grafone T., and Isidori A. Clinical efficacy and antiangiogenic activity of thalidomide in myelofibrosis with myeloid metaplasia. A pilot study Leukemia 16 2002 1609 1614
68. Elliott M.A., Mesa R.A., Li C.Y., Hook C.C., Ansell S.M., and Levitt R.M. Thalidomide treatment in myelofibrosis with myeloid metaplasia Br J Haematol 117 2002 288 296
69. Bonn D. Thalidomide: no benefit in myelofibrosis with myeloid metaplasia Lancet Oncol 4 2003 70
70. Merup M., Kutti J., Birgergard G., Mauritzson N., Bjorkholm M., and Markevarn B. Negligible clinical effects of thalidomide in patients with myelofibrosis with myeloid metaplasia Med Oncol 19 2002 79 86
71. Greenberg P., Cox C., LeBeau M.M., Fenaux P., Morel P., and Sanz G. International scoring system for evaluating prognosis in myelodysplastic syndromes Blood 89 1997 2079 2088
72. Yoshida Y., and Mufti G.J. Apoptosis and its significance in MDS: controversies revisited Leuk Res 23 1999 777 785
73. Bellamy W.T., Richter L., Sirjani D., Roxas C., Glinsmann-Gibson B., and Frutiger Y. Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes Blood 97 2001 1427 1434
74. Aguayo A., Kantarjian H.M., Estey E.H., Giles F.J., Verstovsek S., and Manshouri T. Plasma vascular endothelial growth factor levels have prognostic significance in patients with acute myeloid leukemia but not in patients with myelodysplastic syndromes Cancer 95 2002 1923 1930
75. Pruneri G., Bertolini F., Soligo D., Carboni N., Cortelezzi A., and Ferrucci P.F. Angiogenesis in myelodysplastic syndromes Br J Cancer 81 1999 1398 1401
76. Tsirigotis P., Venetis E., Rontogianni D., Dervenoulas J., Kontopidou F., and Apostolidis P. Thalidomide in the treatment of myelodysplastic syndrome with fibrosis Leuk Res 26 2002 965 966
77. Raza A., Dutt D., Lisak L., Dean L., Fantroy L., and Gezer S. Combination of thalidomide and Enbrel for the treatment of patients with myelodysplastic syndromes (MDS) Blood 98 2001 273b
78. Raza A., Lisak L., Dutt D., Dean L., Fantroy L., and Syed E. Combination of thalidomide with pentoxifylline, ciprofloxacin and dexamethasone (PCD) in patients with myelodysplastic syndromes (MDS) Blood 98 2001 273b
79. Steurer M., Sudmeier I., Stauder R., and Gastl G. Thromboembolic events in patients with myelodysplastic syndrome receiving thalidomide in combination with darbepoietin-alpha Br J Haematol 121 2003 101 103
80. Cortes J., Kantarjian H., Albitar M., Thomas D., Faderl S., and Koller C. A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome Cancer 97 2003 1234 1241
81. Hussong J.W., Rodgers G.M., and Shami P.J. Evidence of increased angiogenesis in patients with acute myeloid leukemia Blood 95 2000 309 313
82. Steins M.B., Padro T., Bieker R., Ruiz S., Kropff M., and Kienast J. Efficacy and safety of thalidomide in patients with acute myeloid leukemia Blood 99 2002 834 839
83. Kneller A., Raanani P., Hardan I., Avigdor A., Levi I., and Berkowicz M. Therapy with thalidomide in refractory multiple myeloma patients - the revival of an old drug Br J Haematol 108 2000 391 393
84. Rajkumar S.V., Fonseca R., Dispenzieri A., Lacy M.Q., Lust J.A., and Witzig T.E. Thalidomide in the treatment of relapsed multiple myeloma Mayo Clin Proc 75 2000 897 901
85. Juliusson G., Celsing F., Turesson I., Lenhoff S., Adriansson M., and Malm C. Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma Br J Haematol 109 2000 89 96
86. Blade J., Esteve J., Rosinol L., Perales M., Montoto S., and Tuset M. Thalidomide in refractory and relapsing multiple myeloma Semin Oncol 28 2001 588 592
87. Tosi P., Zamagni E., Cellini C., Ronconi S., Patriarca F., and Ballerini F. Salvage therapy with thalidomide in patients with advanced relapsed/refractory multiple myeloma Haematologica 87 2002 408 414
88. Kumar S., Gertz M.A., Dispenzieri A., Lacy M.Q., Geyer S.M., and Iturria N.L. Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myeloma Mayo Clin Proc 78 2003 34 39
89. Palumbo A., Giaccone L., Bertola A., Pregno P., Bringhen S., and Rus C. Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma Haematologica 86 2001 399 403
90. Dimopoulos M.A., Zervas K., Kouvatseas G., Galani E., Grigoraki V., and Kiamouris C. Thalidomide and dexamethasone combination for refractory multiple myeloma Ann Oncol 12 2001 991 995
91. Anagnostopoulos A., Weber D., Rankin K., Delasalle K., and Alexanian R. Thalidomide and dexamethasone for resistant multiple myeloma Br J Haematol 121 2003 768 771